We are live on ! Find out more

Inovio Pharmaceuticals

INO

Market cap $128M

1.24 USD

+0.03

2.48%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

1.23

-0.01

0.81%

1 day

2.48%

5 days

0%

1 month

3.33%

3 months

10.71%

6 months

-25.3%

Year to date

-26.63%

1 year

-46.32%

5 years

-98.67%

10 years

-98.88%

About: Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.

Employees: 112

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 28.6%

Neutral 71.4%

Negative 0%

Zacks Investment Research

Bet on 4 Top-Ranked Stocks With Rising P/E

Tap four stocks with increasing P/E ratios to try out an out-of-the-box investment approach.

Bet on 4 Top-Ranked Stocks With Rising P/E

Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms

Inovio Pharmaceuticals NASDAQ: INO said its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, or RRP, remains under U.S. Food and Drug Administration review, with a target action date of Oct. 30.

Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms

Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP

Inovio Pharmaceuticals NASDAQ: INO is approaching an October 30 PDUFA date for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis, or RRP, President and CEO Jacky Shea said during a Cantor Fitzgerald fireside chat.

Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP

Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Zacks Investment Research

Bet on 5 Top-Ranked Stocks With Rising P/E

Tap these five stocks - CURI, INO, GDS, NMG and CCOI - with increasing P/E ratios to try out an out-of-the-box approach.

Bet on 5 Top-Ranked Stocks With Rising P/E

INOVIO to Participate in Upcoming Investor Conferences

PLYMOUTH MEETING, Pa., Sept. 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following investor conferences: Cantor Global Healthcare Conference (New York) Date: Wednesday, September 9 Fireside Chat: 3:20 PM ET Webcast: https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=99315971&checkCompany=1&checkEmail=1&checkName=1 H.C.

INOVIO to Participate in Upcoming Investor Conferences

Inovio Pharmaceuticals Q2 Earnings Call Highlights

Inovio Pharmaceuticals NASDAQ: INO said the U.S. Food and Drug Administration has completed several key steps in its review of the company's biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis, or RRP, while the company continues preparations for a potential commercial launch.

Inovio Pharmaceuticals Q2 Earnings Call Highlights

Inovio Pharmaceuticals, Inc. (INO) Q2 2026 Earnings Call Transcript

Inovio Pharmaceuticals, Inc. (INO) Q2 2026 Earnings Call Transcript

Inovio Pharmaceuticals, Inc. (INO) Q2 2026 Earnings Call Transcript

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026 Commercial preparations advancing in anticipation of potential product launch for INO-3107 Positive topline results reported from Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia patients by ApolloBio, INOVIO's partner in China Presented promising data from next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at several scientific conferences Current cash, cash equivalents, and short-term investments anticipated to fund operations into late first quarter 2027, through a potential launch of INO-3107, if approved PLYMOUTH MEETING, Pa., Aug. 12, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter ended June 30, 2026 and provided an update on recent company developments.

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

See News Rankings

Price charts implemented using Lightweight Charts™